Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

NCT01027676 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT01027676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01027676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
Lead sponsor
National Cancer Center, Korea
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2010
Completion date
March 31, 2014
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma